New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 26, 2014
08:33 EDTCBMGCellular Biomedicine completes enrollment in ReJoin Phase IIb clinical trial
Cellular Biomedicine has completed the patient enrollment required for its Phase IIb trial to further evaluate the safety and efficacy of their proprietary adipose-derived mesenchymal precursor cell-based therapy ReJoin for Knee Osteoarthritis. The Phase I/IIa clinical trial for this therapy was completed in 4Q13. The primary endpoints for this trial are knee-related pain, stiffness and function.
News For CBMG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 25, 2015
10:00 EDTCBMGCellular Biomedicine announces phase I results from CAR-T program
Subscribe for More Information
09:10 EDTCBMGCellular Biomedicine announces interim results from ReJoin Phase IIb trial
Cellular Biomedicine Group announced interim 24-week clinical data from the Phase IIb trial of its ReJoin human adipose-derived mesenchymal progenitor cell, or haMPC, therapy for Knee Osteoarthritis, or KOA. The 24-week interim data shows the primary and secondary endpoints of ReJoin therapy group have all improved significantly compared to their baseline, which has confirmed the Phase IIa report, although only the change of WOMAC, the primary endpoint, is significantly higher than that of the ARTZŅ control group. A trend of improvement of the secondary endpoints, including cartilage MRI quantification, is observable at the 24th week. The company expects the final results to be available at the end of 2015.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use